NCT02058940View on ClinicalTrials.gov

Intravenous Exenatide in Patients With Acute Brain Injury

PHASE4CompletedINTERVENTIONAL

Enrollment

8

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

August 31, 2017

Study Completion Date

August 31, 2017

Conditions

Brain Injuries

Interventions

DRUG

Exenatide

50 ng/min IV for 30 minutes, then start 25 ng/min IV for a maximum duration of 48 hours

Trial Locations (1)

27599

University of North Carolina; UNC Medical Center, Chapel Hill

Sponsors

Collaborators (2)

All Listed Sponsors

collaborator

AstraZeneca

INDUSTRY

collaborator

Medtronic

INDUSTRY

lead

University of North Carolina, Chapel Hill

OTHER